Payment overview · 2025
General Payments
$4,682.79
216 reported records · 39 companies
Healthcare provider profile · identity verified
Frank Puhalovich, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · CUMMING, GA · NPI 1548253941
Verified facts
What the public records show
CMS Open Payments records show Frank Puhalovich, M.D. received $4,682.79 in general payments during 2025 across 216 reported records.
PFIZER INC. accounted for 12.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 49 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Ingrezza, Nuplazid, Nurtec Odt, Qulipta, Ubrelvy, Vumerity.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nuplazid by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Vumerity by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Eliquis by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xadago as an associated drug or biological on 139 records involving 79 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xadago by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $602.44 | 12.9% | 46 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $324.94 | 6.9% | 27 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $298.56 | 6.4% | 12 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $290.59 | 6.2% | 8 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $270.78 | 5.8% | 12 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $253.28 | 5.4% | 9 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $243.13 | 5.2% | 10 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $219.14 | 4.7% | 7 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $204.31 | 4.4% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $197.84 | 4.2% | 8 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $183.58 | 3.9% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $145.54 | 3.1% | 5 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $139.21 | 3.0% | 5 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $128.86 | 2.8% | 4 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $124.88 | 2.7% | 5 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $87.95 | 1.9% | 4 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $85.28 | 1.8% | 4 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $75.17 | 1.6% | 4 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $72.15 | 1.5% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $71.02 | 1.5% | 2 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $66.33 | 1.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $55.29 | 1.2% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.36 | 1.0% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $48.35 | 1.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.05 | 1.0% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $42.19 | 0.9% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $40.42 | 0.9% | 2 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $36.72 | 0.8% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $33.49 | 0.7% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.48 | 0.7% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $31.38 | 0.7% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $30.76 | 0.7% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $29.89 | 0.6% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $27.11 | 0.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.24 | 0.5% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$21.13 | 0.5% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $19.90 | 0.4% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $19.14 | 0.4% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.91 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,641.29 | 215 |
| Education | $41.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $464.32 | 40 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $273.91 | 11 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $273.91 | 11 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $270.78 | 12 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $267.78 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $265.66 | 24 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $253.28 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $242.05 | 22 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $221.53 | 21 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $219.14 | 7 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $201.47 | 5 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $197.84 | 8 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $183.58 | 7 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $177.48 | 6 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $138.12 | 6 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $138.12 | 6 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $124.88 | 5 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $87.95 | 4 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $83.33 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $82.12 | 3 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $75.17 | 4 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $72.15 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $71.02 | 2 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $66.33 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $62.21 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $61.09 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $56.35 | 2 | 2025 |
Source payment records
|
|||||
| AVONEX Normalized: avonex |
Biological | Biogen, Inc. | $55.65 | 3 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $48.36 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $48.35 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | MDD US Operations, LLC | $46.02 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $45.05 | 2 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $42.19 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $41.20 | 2 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $40.42 | 2 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $37.07 | 2 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $36.72 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $33.49 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $33.48 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $32.77 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $31.38 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $29.89 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $7.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 32 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
32 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Xadago open payments reported associated product |
CMS Open Payments — General Payments 139 supporting records · 79 recipient NPIs · example record 1241843808 |
Xadago · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 529 | 151 |
| Gabapentin | Gabapentin | 403 | 110 |
| Memantine Hcl | Memantine Hcl | 370 | 96 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 307 | 80 |
| Levetiracetam | Levetiracetam | 283 | 73 |
| Clonazepam | Clonazepam | 282 | 41 |
| Alprazolam | Alprazolam | 211 | 53 |
| Lamotrigine | Lamotrigine | 209 | 53 |
| Topiramate | Topiramate | 184 | 43 |
| Amantadine | Amantadine Hcl | 162 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 143 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 143 | 18 |
| Primidone | Primidone | 138 | 33 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 137 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 122 | 33 |
| Nortriptyline Hcl | Nortriptyline Hcl | 110 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 109 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 33 |
| Rasagiline Mesylate | Rasagiline Mesylate | 105 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 18 |
| Trazodone Hcl | Trazodone Hcl | 96 | 31 |
| Lorazepam | Lorazepam | 94 | 18 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 92 | 14 |
| Aimovig Autoinjector | Erenumab-Aooe | 85 | 11 |
| Diazepam | Diazepam | 85 | 12 |
| Lacosamide | Lacosamide | 81 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 80 | 20 |
| Mirtazapine | Mirtazapine | 79 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 77 | 13 |
| Bupropion Xl | Bupropion Hcl | 71 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 16 |
| Prednisone | Prednisone | 65 | 31 |
| Carbamazepine Er | Carbamazepine | 64 | 20 |
| Baclofen | Baclofen | 62 | 18 |
| Emgality Pen | Galcanezumab-Gnlm | 60 | 15 |
| Propranolol Hcl | Propranolol Hcl | 56 | 19 |
| Promethazine Hcl | Promethazine Hcl | 52 | 12 |
| Ubrelvy | Ubrogepant | 51 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 47 | 16 |
| Zonisamide | Zonisamide | 46 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | suppressed |
| Pregabalin | Pregabalin | 43 | 13 |
| Aripiprazole | Aripiprazole | 42 | 13 |
| Ondansetron Odt | Ondansetron | 41 | 11 |
| Memantine Hcl Er | Memantine Hcl | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Phenobarbital | Phenobarbital | 38 | suppressed |
| Carbamazepine | Carbamazepine | 37 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 37 | 13 |
| Eliquis | Apixaban | 35 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 35 | suppressed |
| Rivastigmine | Rivastigmine | 34 | suppressed |
| Neupro | Rotigotine | 33 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 33 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 33 | 14 |
| Vumerity | Diroximel Fumarate | 33 | suppressed |
| Botox | Onabotulinumtoxina | 32 | 13 |
| Buprenorphine | Buprenorphine | 32 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Xadago | Safinamide Mesylate | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 27 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 27 | suppressed |
| Qulipta | Atogepant | 27 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 26 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Ingrezza | Valbenazine Tosylate | 23 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 18 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 17 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Felbamate | Felbamate | 15 | suppressed |
| Copaxone | Glatiramer Acetate | 14 | suppressed |
| Entacapone | Entacapone | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Almotriptan Malate | Almotriptan Malate | 12 | suppressed |
| Droxidopa | Droxidopa | 12 | suppressed |
| Fioricet | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 12 | suppressed |
| Keppra | Levetiracetam | 12 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 12 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 11 | suppressed |
| Nourianz | Istradefylline | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,682.79 · 216 records | PFIZER INC. | AMYVID, AUSTEDO XR, AVONEX, BOTOX, BRIUMVI, Briviact, CREXONT, Dysport, ELYXYB - CELECOXIB, EPIDIOLEX, FYCOMPA, Gamunex-C, HORIZANT, INGREZZA, KESIMPTA, KISUNLA, LEQEMBI, LUMRYZ, Motpoly XR, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus Zunovo, PANZYGA, PONVORY, QULIPTA, Qelbree, REXULTI, Rystiggo, Sunosi, Symbravo, TANLOR, TRUDHESA, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VRAYLAR, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, WAINUA, WAKIX, ZAVZPRET, ZEPOSIA | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error